Literature DB >> 10869371

A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism.

K Kristiansen1, W K Kroeze, D L Willins, E I Gelber, J E Savage, R A Glennon, B L Roth.   

Abstract

Discovering the molecular and atomic mechanism(s) by which G-protein-coupled receptors (GPCRs) are activated by agonists remains an elusive goal. Recently, studies examining two representative GPCRs (rhodopsin and alpha(1b)-adrenergic receptors) have suggested that the disruption of a putative "salt-bridge" between highly conserved residues in transmembrane (TM) helix III, involving aspartate or glutamate, and helix VII, involving a basic residue, results in receptor activation. We have tested whether this is a general mechanism for GPCR activation by constructing a model of the 5-hydroxytryptamine (5-HT)(2A) receptor and characterizing several mutations at the homologous residues (Asp-155 and Asn-363) of the 5-HT(2A) serotonin receptor. All of the mutants (D155A, D155N, D155E, D155Q, and S363A) resulted in receptors with reduced basal activity; in no case was evidence for constitutive activity revealed. Structure-function studies with tryptamine analogs and various Asp-155 mutants demonstrated that Asp-155 interacts with the terminal, and not indole, amine moiety of 5-HT(2A) agonists. Interestingly, the D155E mutation interfered with the membrane targeting of the 5-HT(2A) receptor, and an inverse relationship was discovered when comparing receptor activation and targeting for a series of Asp-155 mutants. This represents the first known instance in which a charged residue located in a putative TM helix alters the membrane targeting of a GPCR. Thus, for 5-HT(2A) receptors, the TMIII aspartic acid (Asp-155) is involved in anchoring the terminal amine moiety of indole agonists and in membrane targeting and not in receptor activation by salt-bridge disruption.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869371

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  Native serotonin membrane receptors recognize 5-hydroxytryptophan-functionalized substrates: enabling small-molecule recognition.

Authors:  Amit Vaish; Mitchell J Shuster; Sarawut Cheunkar; Yogesh S Singh; Paul S Weiss; Anne M Andrews
Journal:  ACS Chem Neurosci       Date:  2010-04-09       Impact factor: 4.418

2.  Chemotype-selective modes of action of κ-opioid receptor agonists.

Authors:  Eyal Vardy; Philip D Mosier; Kevin J Frankowski; Huixian Wu; Vsevolod Katritch; Richard B Westkaemper; Jeffrey Aubé; Raymond C Stevens; Bryan L Roth
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

Review 3.  Remote control of neuronal signaling.

Authors:  Sarah C Rogan; Bryan L Roth
Journal:  Pharmacol Rev       Date:  2011-03-17       Impact factor: 25.468

Review 4.  Structure and function of serotonin G protein-coupled receptors.

Authors:  John D McCorvy; Bryan L Roth
Journal:  Pharmacol Ther       Date:  2015-01-17       Impact factor: 12.310

5.  Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.

Authors:  Mario de la Fuente Revenga; Urjita H Shah; Nima Nassehi; Alaina M Jaster; Prithvi Hemanth; Salvador Sierra; Malgorzata Dukat; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2021-01-05       Impact factor: 4.418

6.  A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action.

Authors:  Ola M Ghoneim; Diaa A Ibrahim; Ibrahim M El-Deeb; So Ha Lee; Raymond G Booth
Journal:  Bioorg Med Chem Lett       Date:  2011-09-21       Impact factor: 2.823

Review 7.  Optogenetic and chemogenetic techniques for neurogastroenterology.

Authors:  Werend Boesmans; Marlene M Hao; Pieter Vanden Berghe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-29       Impact factor: 46.802

Review 8.  Engineering GPCR signaling pathways with RASSLs.

Authors:  Bruce R Conklin; Edward C Hsiao; Sylvie Claeysen; Aline Dumuis; Supriya Srinivasan; John R Forsayeth; Jean-Marc Guettier; W C Chang; Ying Pei; Ken D McCarthy; Robert A Nissenson; Jürgen Wess; Joël Bockaert; Bryan L Roth
Journal:  Nat Methods       Date:  2008-08       Impact factor: 28.547

9.  Molecular interactions between general anesthetics and the 5HT2B receptor.

Authors:  Felipe Matsunaga; Lu Gao; Xi-Ping Huang; Jeffery G Saven; Bryan L Roth; Renyu Liu
Journal:  J Biomol Struct Dyn       Date:  2013-12-23

10.  Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists.

Authors:  Thibault Varin; Hugo Gutiérrez-de-Terán; Marián Castro; José Brea; Frederic Fabis; François Dauphin; Johan Aqvist; Alban Lepailleur; Pilar Perez; Javier Burgueño; José Miguel Vela; Maria Isabel Loza; Jordi Rodrigo
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.